| 7.99 0.36 (4.72%) | 04-26 10:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.85  |
1-year : | 12.07 |
| Resists | First : | 9.29 |
Second : | 10.34 |
| Pivot price | 8.47 |
|||
| Supports | First : | 7.61 | Second : | 6.33 |
| MAs | MA(5) : | 7.92 |
MA(20) : | 8.76 |
| MA(100) : | 9.83 |
MA(250) : | 13.45 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 6.5 |
D(3) : | 10.8 |
| RSI | RSI(14): 26.5  |
|||
| 52-week | High : | 27.47 | Low : | 7.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VIR ] has closed above bottom band by 20.3%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8 - 8.06 | 8.06 - 8.1 |
| Low: | 7.51 - 7.56 | 7.56 - 7.6 |
| Close: | 7.56 - 7.64 | 7.64 - 7.71 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Thu, 25 Apr 2024
Biopharma Layoff Tracker 2024: BMS, CureVac, Tessera and More Cut Staff - BioSpace
Wed, 24 Apr 2024
What Makes Vir Biotechnology (VIR) a New Buy Stock - Zacks Investment Research
Thu, 18 Apr 2024
Vir Biotechnology Inc. (VIR) Announces CFO Departure - StreetInsider.com
Thu, 11 Apr 2024
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 - Business Wire
Sat, 06 Apr 2024
Have Vir Biotechnology Insiders Been Selling Stock? - Simply Wall St
Thu, 04 Apr 2024
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 135 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 76.2 (%) |
| Shares Short | 4,960 (K) |
| Shares Short P.Month | 5,080 (K) |
| EPS | -4.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.8 |
| Profit Margin | 0 % |
| Operating Margin | -724.6 % |
| Return on Assets (ttm) | -17.5 % |
| Return on Equity (ttm) | -33.6 % |
| Qtrly Rev. Growth | -66 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.63 |
| EBITDA (p.s.) | -4.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -779 (M) |
| Levered Free Cash Flow | -596 (M) |
| PE Ratio | -1.69 |
| PEG Ratio | -0.3 |
| Price to Book value | 0.65 |
| Price to Sales | 12.12 |
| Price to Cash Flow | -1.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|